APACT Trial in Pancreatic Adenocarcinoma

obr has 860 videos Subscribe Here

Description: Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center shares the results from the APACT study, a phase III trial involving adjuvant nab-paclitaxel plus gemcitabine versus gemcitabine alone for surgically resected pancreatic adenocarcinoma.
Shared By : obr
Posted on : 07/02/19
Added : 19 days ago
Category : Colorectal Cancer